Pancuronium-induced prolonged neuromuscular blockade.
Rossiter
A
A
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.
Souney
P F
PF
McGowan
S
S
Carvajal
P
P
D000328:Adult; D000368:Aged; D002985:Clinical Protocols / Q000592:standards; D003937:Diagnosis, Differential; D004357:Drug Synergism; D004576:Electromyography; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009133:Muscular Atrophy / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D009431:Neural Conduction; D010197:Pancuronium / Q000008:administration & dosage / Q000009:adverse effects*; D010243:Paralysis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D026741:Physical Therapy Modalities
D006993:Hypnotics and Sedatives; D010197:Pancuronium